Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › alectinib

alectinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of alectinib

14 trials tracked of alectinib: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 699 citations.

14Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 5 Phase 1 3 Other / NA 3
  1. Phase 3 A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants Completed · 699 cited
  2. Phase 3 Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib Completed · 346 cited
  3. Phase 3 A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer Completed · 51 cited
  4. Phase 2 A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Completed
  5. Phase 2 A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Completed
  6. Phase 2 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Completed
Show 8 more trials
  1. Phase 2 A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment Completed
  2. Phase 2 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed
  3. Phase 1 Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib Completed
  4. Phase 1 A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers Completed
  5. Phase 1 A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers. Completed
  6. N/A Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns Completed
  7. N/A Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. Completed
  8. N/A A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41)
Oncology Phase III
Alectinib improves progression-free survival over crizotinib in ALK-positive NSCLC (HR 0.41) Alectinib Shows Better Progression-Free Survival Than Crizotinib for NSCLC
This pooled analysis of Phase III trials involving 500 patients with ALK-positive NSCLC found that alectinib significantly improved progress…
Alectinib showed better progression-free survival than crizotinib in a study of 500 patients with ALK-positive lung cancer.
Jul 27, 2026
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
Drug Pipeline Guideline
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Frontiers May 24, 2026